Immunoprecise Antibodies Ltd

ImmunoPrecise Antibodies Ltd. is a therapeutic antibody discovery company, which engages in the provision of human therapeutic antibody discovery and development services. The firm offers a selection of antibodies, enzymes, enzymes activity assays, arthritis animal products, proteins, deiminated proteins, and hybridoma licensing for research purposes. Its services include B cell sorting, screening and sequencing; custom, immune and naive phage display production and screening; bi-specific, tri-specific, VHH, and VNAR antibody manufacturing; antibody engineering; and antibody optimization and humanization. The company was founded by Robert Beecroft on November 22, 1983 and is headquartered in Victoria, Canada.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

IPA reports record revenue and seeks funding for future growth

IPA's Q2 '23 earnings call highlighted record revenue, strategic program consolidation, and advancements in R&D. While facing cash needs and the need to raise funds, the company remains optimistic about future partnerships and the potential for data management transactions.

Immunoprecise Antibodies reports strong revenue growth and strategic collaborations

Immunoprecise Antibodies Ltd (IPA) had a strong quarter with revenue growth and valuable research collaborations, positioning the company for future success despite operational challenges.
IPA's focus on innovation, disruptive AI-driven collaborations, and strategic changes to boost profits highlight a positive growth trajectory and commitment to addressing unmet medical needs.

Immunoprecise Antibodies reports record revenue, eyes strategic partnerships for growth

IPA's Q4 '23 earnings call reflects strong revenue growth, strategic collaborations, and a focus on operational efficiency, positioning the company for future success.
While facing financial challenges and the need for fundraising, IPA's technological strengths, partnerships, and market opportunities offer avenues for growth and innovation.
The company's performance highlights resilience in the biotech sector, with a clear roadmap for enhancing shareholder value and advancing R&D capabilities.

Immunoprecise Antibodies Ltd posts strong Q1 earnings, eyes U.S. investors

Immunoprecise Antibodies Ltd (IPA) reports robust Q1 2024 earnings, marked by significant revenue growth and improved financial metrics. The company showcases strengths in strategic leadership, cost management, and expansion initiatives, while facing challenges in managing net losses and financial transparency. IPA has opportunities to capitalize on its strengths and attract more investors through the SEC shelf offering.

Immunoprecise Antibodies Ltd reports record Q2 revenue growth

IPA's Q2 2024 earnings call showcased robust revenue growth, operational improvements, and strategic initiatives driving the company forward.
While facing industry challenges, IPA's focus on client trust, cost management, and innovation positions it well for future success.
The company's commitment to governance, shareholder engagement, and exploring new revenue streams highlights a proactive approach to growth.

Immunoprecise Antibodies Ltd (IPA) reports strong Q3 performance and strategic investments

Immunoprecise Antibodies Ltd (IPA) delivered a robust performance in Q3 2024, marked by revenue growth, profit margin improvements, and strategic investments in BioStrand. While facing a net loss, IPA maintains a healthy cash balance and focuses on R&D efficiency. The company's strengths in innovation and customer commitment position it well for future growth, with opportunities to leverage its momentum for market expansion.

Immunoprecise Antibodies (IPA) reports 19% revenue growth in 2024

Immunoprecise Antibodies Ltd (IPA) delivered strong financial performance in fiscal year 2024, with revenue growth, reduced operating expenses, and successful product launches. Strategic collaborations and industry recognition highlight IPA's competitive strengths. Addressing commercialization challenges and seizing growth opportunities will be key focus areas for future success.

Immunoprecise Antibodies reports revenue growth and strategic advancements in Q1

IPA's Q1 2025 performance reflects revenue growth driven by VHH antibody programs and strategic inventory management.
The company's strengths lie in its AI-driven platform, strong pipeline, and balanced revenue generation models.
Challenges include maintaining financial consistency, effective inventory management, and staying competitive in the evolving market.
Opportunities for IPA include sustained growth through fee-for-service work, revenue diversification via licensing, and leadership in biotechnology innovation.

Immunoprecise Antibodies reports revenue growth amidst financial challenges in Q2 2025

Immunoprecise Antibodies Ltd's Q2 2025 performance reflects revenue growth but also increased expenses and a net loss, highlighting financial challenges.
Strategic strengths include industry profile enhancement, strong research collaborations, and a commitment to innovation.
Challenges lie in cost management, operational realignment post-divestiture, and the need for revenue growth.
Opportunities exist in collaborations with semiconductor companies, market expansion through BioStrand, and strategic financial restructuring.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ImmunoPrecise Antibodies Ltd. is a therapeutic antibody discovery company, which engages in the provision of human therapeutic antibody discovery and development services. The firm offers a selection of antibodies, enzymes, enzymes activity assays, arthritis animal products, proteins, deiminated proteins, and hybridoma licensing for research purposes. The company was founded by Robert Beecroft on November 22, 1983 and is headquartered in Victoria, Canada.

DIEPENBEEK, Belgium--(BUSINESS WIRE)---- $IPA #AI--Diepe IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA) is pleased to share that IPA's subsidiary Biostrand, a Belgian end-to-end multi-omics analysis platform provider, has received a €460,000 round of grant funding from VLAIO (Flanders Innovation & Entrepreneurship), the research fund of the Flemish regional government in Belgium. Conditionally awarded in January this year, BioStrand recently satisfied the remainin

IPA's Subsidiary BioStrand Secures Second VLAIO Research Grant

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA) is pleased to share the outcome of recent laboratory data on their PolyTope® TATX-03 antibody cocktail, which demonstrates strong neutralizing activity toward the Omicron subvariant BA.2. The BA.2 pseudovirus was neutralized with a potency comparable to the previously analyzed Omicron BA.1, demonstrating ongoing and continued consistency of the cocktail to potently

IPA's Advanced PolyTope® TATX-03, a Multi-Antibody Cocktail, Potently Prevents In Vitro Infection of Cells by the Currently Dominant Omicron Sublineage BA.2, in Addition to all Other Variants of Concern

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA) is pleased to announce that it has completed its previously announced acquisition of control over BioStrand BV, BioKey BV, and BioClue BV (hereinafter collectively referred to as “BioStrand”), a group of Belgian biotech entities and pioneers in the field of bioinformatics and biotechnology, through its wholly owned subsidiary ImmunoPrecise Netherlands BV. “Uniting

IPA Completes Acquisition of Belgian Technology Companies BioStrand, BioKey, and BioClue – Adding Artificial Intelligence-Driven Analytics to its Antibody Discovery Capabilities and Offerings

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #DHA--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA) is pleased to announce that it has entered into a definitive share purchase agreement (SPA) to acquire, through its wholly-owned subsidiary ImmunoPrecise Netherlands BV, control over BioStrand BV, BioKey BV, and BioClue BV (hereinafter collectively referred to as “BioStrand”), a group of Belgian biotech entities and pioneers in the field of bioinformatics and biote

IPA Announces Agreement to Acquire BioStrand BV – Revolutionizing Biotherapeutics with Methodology to Encode Omics and Power Drug Development with Advanced Artificial Intelligence

ImmunoPrecise Antibodies Ltd. (IPA) CEO Jennifer Bath on Q3 2022 Results - Earnings Call Transcript

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #DHA--IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA), a leader in full-service therapeutic antibody discovery and development, today announced financial results for third quarter fiscal year 2022, which ended January 31, 2022. Third Quarter Fiscal Year 2022 Financial Summary* (All comparisons are to the period ended January 31, 2022) The Company achieved Project revenue of $4.1 million, an increase of $0.7 million o

ImmunoPrecise Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2022

Elektrofi and Immunoprecise Antibodies Ltd (NASDAQ: IPA) have collaborated to explore a high-concentration formulation of IPA's COVID-19 antibody cocktail, PolyTope TATX-03.  The collaboration aims to generate an IND-enabling data package for the FDA for an.

Immunoprecise, Elektrofi To Pursue Low-Volume Injectable Formulation Of IPA's COVID-19 Antibody Cocktail

BOSTON--(BUSINESS WIRE)---- $IPA #DHA--Elektrofi (ELEKTROFI, INC) & IPA (IMMUNOPRECISE ANTIBODIES LTD.) (NASDAQ: IPA) (TSXV: IPA) today announced they are entering into a collaboration to explore a high-concentration formulation of IPA's COVID-19 antibody cocktail, PolyTope® TATX-03. This collaboration aims to generate an IND-enabling data package for the FDA for an alternatively formulated version of TATX-03, named TATX-03E, that could be easily self-administered in a non-healthcare setting. By joining

IPA Selected to Work with Elektrofi on COVID-19 Therapeutic Delivery and Future Pandemic Preparation under SBIR Contract from Defense Health Agency within US Department of Defense

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #Deltavariant--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company”) (NASDAQ: IPA) (TSXV: IPA) is pleased to report on the latest progress in the development of their PolyTope® TATX-03 antibody cocktail therapy with a proven strong efficacy against all tested SARS-CoV-2 variants-of-concern. The Company reports positive data indicating their recent IND-enabling animal studies do not show any observable acute adverse events, data which supports a highly positive safety

IPA Updates on Investigational New Drug (IND) Enabling Program for PolyTope® TATX-03

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #Deltavariant--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced today announced that it will host a conference call to discuss its financial results and recent business highlights for third quarter fiscal year 2022, on Wednesday, March 16th, 2022, at 10:30 a.m. ET. The financial results will be issued in a press release prior to the call.

ImmunoPrecise Sets Third Quarter Fiscal 2022 Financial Results and Recent Business Highlights Conference Call for Wednesday, March 16th at 10:30 a.m. ET

Immunoprecise Antibodies Ltd IPA has released preclinical data for the PolyTope TATX-03 COVID-19 antibody cocktail. [ALERT] Nic Chahine shares his Bear Market Beating options trading strategy.

ImmunoPrecise's COVID-19 Antibody Cocktail Shows Neutralization Activity Against Omicron

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #Deltavariant--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company”) (NASDAQ: IPA) (TSXV: IPA) is pleased to announce the release of data demonstrating strong neutralizing potency of its PolyTope® TATX-03 antibody cocktail towards the SARS-CoV-2 Omicron variant (B.1.1.529) in in vitro pseudovirus assays. This first generation four antibody cocktail against SARS-CoV-2 was rationally designed to sustain efficacy against all SARS-CoV-2 strains and variants with the goal

Immunotherapeutic PolyTope® from ImmunoPrecise (IPA) Potently Neutralizes the SARS-CoV-2 Omicron Variant – Moves Towards FDA/IND-Submission

VICTORIA, British Columbia & OSS, Netherlands--(BUSINESS WIRE)---- $IPA #Deltavariant--IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) today announced the relocation of its IPA Europe Oss laboratories to a new multi-tenant biotech Center of Excellence at the Pivot Park Campus in Oss, Netherlands. The Company previously announced the move of its IPA Europe laboratories in Utrecht to the new Accelerator building at the Utrecht Science Park this year. IPA leased new space at Pivot

ImmunoPrecise Relocates European Subsidiary to LEED Certified Campus to Continue to Advance its Antibody Research Operations and Environmental Sustainability

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #Deltavariant--IMMUNOPRECISE ANTIBODIES LTD. (“IPA” or the “Company”) (NASDAQ: IPA) (TSXV: IPA), a leader in full-service, therapeutic antibody discovery, today announced that on January 13, 2022 its board of directors approved the grant of 15,000 stock options (the “Options”) under its stock option plan to acquire up to an aggregate of 15,000 common shares in the capital of IPA (“Common Shares”). The Options were granted to a certain officer of IPA. Each Option is

ImmunoPrecise Antibodies Announces Grant of Stock Options

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #Deltavariant--IMMUNOPRECISE ANTIBODIES LTD. (“IPA” or the “Company”) (NASDAQ: IPA) (TSX VENTURE: IPA) and ChemPartner Biologics Co. Ltd. (“ChemPartner”) today announced their global antibody manufacturing collaboration under which ChemPartner will manufacture and supply to IPA's specifications IPA's proprietary PolyTope® TATX-03 Therapy, a rationally designed four monoclonal antibody cocktail developed for use in human clinical trial for the potential prevention a

ImmunoPrecise Antibodies and ChemPartner Biologics Announce PolyTope® TATX-03 Antibody Cocktail Manufacturing Collaboration

ImmunoPrecise Antibodies Ltd.'s (IPA) CEO Dr. Jennifer Bath on Q2 2022 Results - Earnings Call Transcript

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #Deltavariant--IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA), a leader in full-service therapeutic antibody discovery and development, today announced financial results for second quarter fiscal year 2022, which ended October 31, 2021. Second Quarter Fiscal Year 2022 Financial Summary* The Company achieved revenues of $4.7 million, a decrease of $32,780 or (0.7%) from the same period last year**. The Company, primarily thro

ImmunoPrecise Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2022

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #Deltavariant--IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) is providing an update on its Polytope™ Development Program. The Company continues to rapidly progress it SARS-CoV-2 multi-antibody cocktail therapy, PolytopeTM, and has met the following milestones: U.S. Food and Drug Administration assessed IPA's pre-investigational new drug application; preclinical safety studies have now commenced as previously scheduled. IPA

ImmunoPrecise Update on its SARS-CoV-2 PolyTope™ Multi-Antibody Cocktail Development Program

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #Deltavariant--IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) is presenting at the Benchmark Company's Discovery One-on-One Virtual Video Investor Conference. The conference is being held on December 2nd, 2021. About the Benchmark Company & Discovery One on One Virtual Video Investor Conference 2021. The Benchmark Company, LLC, is a diversified financial services firm that offers a full suite of investment banking and in

ImmunoPrecise to Present at the Benchmark Company's Discovery One-on-One Virtual Video Investor Conference on Thursday December 2, 2021

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #Deltavariant--IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) announced today that Paul Andreola, a member of the Board of Directors of IPA, has resigned, effective immediately, from the Company's Board of Directors for personal reasons unrelated to the Company. “On behalf of the Company and the Board of Directors, I would like to thank Paul for serving on our Board of Directors. His insightful and experienced contributions

IPA Announces Resignation of Director

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #Deltavariant--IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA), a leader in full-service therapeutic antibody discovery and development, today announced that it has entered into an At-The-Market Distribution Agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC, as sole sales agent (the “Agent”). Under the ATM Agreement, the Company will be entitled, at its discretion and from time-to-time during the term of the

ImmunoPrecise Announces At-The-Market Facility of up to US$50 Million

VICTORIA, British Columbia & CASTRES, France--(BUSINESS WIRE)---- $IPA #Deltavariant--IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) and the Pierre Fabre pharmaceutical group announced today that IPA's subsidiary, Talem Therapeutics LLC (“Talem”), and Pierre Fabre have entered a multi-year, multi-target research collaboration with the goal to discover and develop therapeutics antibodies for up to nine targets. This strategic collaboration is expected to help expand Talem's por

Talem Therapeutics Announces Multi-Target Antibody Discovery Research Collaboration With Pierre Fabre

ImmunoPrecise Antibodies Ltd. (IPA) CEO Jennifer Bath on Q1 2022 Results - Earnings Call Transcript

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #Deltavariant--IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA), a leader in full-service therapeutic antibody discovery and development, today announced financial results for first quarter fiscal year 2022, which ended July 31, 2021. First Quarter Fiscal Year 2022 Financial Summary* Revenues of $4.6 million, up 22% Research and development costs increased to $1.1 million from $309,213 in 2021 The Company recorded a net loss o

ImmunoPrecise Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2022

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #Deltavariant--IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, announced today that its site in Oss, the Netherlands, which is part of the Company's subsidiary, IPA Europe, has been granted a three-year approval for the “Crédit d'Impôt Recherche” (CIR) from the French Ministry of Higher Education and Research. CIR is a French R&D tax credit initiati

News for Immunoprecise Antibodies Ltd Stock (IPA)